Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020

Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020

This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of internal medicine (1960) 2022-03, Vol.182 (3), p.342-345
Hauptverfasser: Gunter, Simon J, Kesselheim, Aaron S, Rome, Benjamin N
Format: Artikel
Sprache:eng
Schlagworte:
Drug Approval
Drug Costs
Drugs, Generic
FDA approval
Health care expenditures
Health Care Policy and Law
Humans
Letters
Medicaid
Online First
Pharmaceutical Preparations
Prescription drugs
Research Letter
United States
United States Food and Drug Administration
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 345
container_issue 3
container_start_page 342
container_title Archives of internal medicine (1960)
container_volume 182
creator Gunter, Simon J
Kesselheim, Aaron S
Rome, Benjamin N
description This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.
doi_str_mv 10.1001/jamainternmed.2021.7614
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8767485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2788299</ama_id><sourcerecordid>2642525019</sourcerecordid><originalsourceid>FETCH-LOGICAL-a464t-9a349b8118a67e2fce73269ed5e697ba8cdeba3325e9b28a0bde41e32f8857f03</originalsourceid><addsrcrecordid>eNpdkV9rFDEUxYNYbKn9Aj5owBdfds2_STIvwlJbFVr60BZfhJCZ3NlmnUmmyUyh396sWxfbvCRwf-dwbg5CHyhZUkLo540drA8TpDCAWzLC6FJJKl6hI0alXkhKxev9m8hDdJLzhpSjCRGcv0GHvCKCaFUdoV-X4HxrvcPXIwTnwxrHgL-meZ3xpU2_YQKHf_rpLs4Tvr3G5zE6bIP7i-CVG3zweUp28kW2GscUH2yPfcAlFnmLDjrbZzh5uo_R7fnZzen3xcXVtx-nq4uFFVJMi9pyUTeaUm2lAta1oDiTNbgKZK0aq1sHjeWcVVA3TFvSOBAUOOu0rlRH-DH6svMd56Z8SQuhJOrNmPxg06OJ1pvnk-DvzDo-GK2kEroqBp-eDFK8nyFPZvC5hb63AeKcDZOMEiYI4QX9-ALdxDmFsl6hBKtYRWhdKLWj2hRzTtDtw1BitiWaZyWabYlmW2JRvv9_l73uX2UFeLcDisF-ypTWrK75HyXypFw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642525019</pqid></control><display><type>article</type><title>Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020</title><source>MEDLINE</source><source>AMA_美国医学会期刊</source><creator>Gunter, Simon J ; Kesselheim, Aaron S ; Rome, Benjamin N</creator><creatorcontrib>Gunter, Simon J ; Kesselheim, Aaron S ; Rome, Benjamin N</creatorcontrib><description>This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.</description><identifier>ISSN: 2168-6106</identifier><identifier>EISSN: 2168-6114</identifier><identifier>DOI: 10.1001/jamainternmed.2021.7614</identifier><identifier>PMID: 35040875</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Drug Approval ; Drug Costs ; Drugs, Generic ; FDA approval ; Health care expenditures ; Health Care Policy and Law ; Humans ; Letters ; Medicaid ; Online First ; Pharmaceutical Preparations ; Prescription drugs ; Research Letter ; United States ; United States Food and Drug Administration</subject><ispartof>Archives of internal medicine (1960), 2022-03, Vol.182 (3), p.342-345</ispartof><rights>Copyright American Medical Association Mar 2022</rights><rights>Copyright 2022 American Medical Association. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a464t-9a349b8118a67e2fce73269ed5e697ba8cdeba3325e9b28a0bde41e32f8857f03</citedby><cites>FETCH-LOGICAL-a464t-9a349b8118a67e2fce73269ed5e697ba8cdeba3325e9b28a0bde41e32f8857f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamainternalmedicine/articlepdf/10.1001/jamainternmed.2021.7614$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2021.7614$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,230,314,780,784,885,3340,27924,27925,76489,76492</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35040875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gunter, Simon J</creatorcontrib><creatorcontrib>Kesselheim, Aaron S</creatorcontrib><creatorcontrib>Rome, Benjamin N</creatorcontrib><title>Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020</title><title>Archives of internal medicine (1960)</title><addtitle>JAMA Intern Med</addtitle><description>This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.</description><subject>Drug Approval</subject><subject>Drug Costs</subject><subject>Drugs, Generic</subject><subject>FDA approval</subject><subject>Health care expenditures</subject><subject>Health Care Policy and Law</subject><subject>Humans</subject><subject>Letters</subject><subject>Medicaid</subject><subject>Online First</subject><subject>Pharmaceutical Preparations</subject><subject>Prescription drugs</subject><subject>Research Letter</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>2168-6106</issn><issn>2168-6114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV9rFDEUxYNYbKn9Aj5owBdfds2_STIvwlJbFVr60BZfhJCZ3NlmnUmmyUyh396sWxfbvCRwf-dwbg5CHyhZUkLo540drA8TpDCAWzLC6FJJKl6hI0alXkhKxev9m8hDdJLzhpSjCRGcv0GHvCKCaFUdoV-X4HxrvcPXIwTnwxrHgL-meZ3xpU2_YQKHf_rpLs4Tvr3G5zE6bIP7i-CVG3zweUp28kW2GscUH2yPfcAlFnmLDjrbZzh5uo_R7fnZzen3xcXVtx-nq4uFFVJMi9pyUTeaUm2lAta1oDiTNbgKZK0aq1sHjeWcVVA3TFvSOBAUOOu0rlRH-DH6svMd56Z8SQuhJOrNmPxg06OJ1pvnk-DvzDo-GK2kEroqBp-eDFK8nyFPZvC5hb63AeKcDZOMEiYI4QX9-ALdxDmFsl6hBKtYRWhdKLWj2hRzTtDtw1BitiWaZyWabYlmW2JRvv9_l73uX2UFeLcDisF-ypTWrK75HyXypFw</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Gunter, Simon J</creator><creator>Kesselheim, Aaron S</creator><creator>Rome, Benjamin N</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220301</creationdate><title>Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020</title><author>Gunter, Simon J ; Kesselheim, Aaron S ; Rome, Benjamin N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a464t-9a349b8118a67e2fce73269ed5e697ba8cdeba3325e9b28a0bde41e32f8857f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Drug Approval</topic><topic>Drug Costs</topic><topic>Drugs, Generic</topic><topic>FDA approval</topic><topic>Health care expenditures</topic><topic>Health Care Policy and Law</topic><topic>Humans</topic><topic>Letters</topic><topic>Medicaid</topic><topic>Online First</topic><topic>Pharmaceutical Preparations</topic><topic>Prescription drugs</topic><topic>Research Letter</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gunter, Simon J</creatorcontrib><creatorcontrib>Kesselheim, Aaron S</creatorcontrib><creatorcontrib>Rome, Benjamin N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of internal medicine (1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gunter, Simon J</au><au>Kesselheim, Aaron S</au><au>Rome, Benjamin N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020</atitle><jtitle>Archives of internal medicine (1960)</jtitle><addtitle>JAMA Intern Med</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>182</volume><issue>3</issue><spage>342</spage><epage>345</epage><pages>342-345</pages><issn>2168-6106</issn><eissn>2168-6114</eissn><abstract>This cross-sectional study examines the proportion of Medicaid prescription and spending on drugs marketed in the United States without Food and Drug Administration approval.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>35040875</pmid><doi>10.1001/jamainternmed.2021.7614</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-6106
ispartof Archives of internal medicine (1960), 2022-03, Vol.182 (3), p.342-345
issn 2168-6106
2168-6114
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8767485
source MEDLINE; AMA_美国医学会期刊
subjects Drug Approval
Drug Costs
Drugs, Generic
FDA approval
Health care expenditures
Health Care Policy and Law
Humans
Letters
Medicaid
Online First
Pharmaceutical Preparations
Prescription drugs
Research Letter
United States
United States Food and Drug Administration
title Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T06%3A47%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medicaid%20Spending%20on%20Drugs%20Marketed%20Without%20US%20Food%20and%20Drug%20Administration%20Approval%20in%202020&rft.jtitle=Archives%20of%20internal%20medicine%20(1960)&rft.au=Gunter,%20Simon%20J&rft.date=2022-03-01&rft.volume=182&rft.issue=3&rft.spage=342&rft.epage=345&rft.pages=342-345&rft.issn=2168-6106&rft.eissn=2168-6114&rft_id=info:doi/10.1001/jamainternmed.2021.7614&rft_dat=%3Cproquest_pubme%3E2642525019%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642525019&rft_id=info:pmid/35040875&rft_ama_id=2788299&rfr_iscdi=true